Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 220 entries
Sorted by: Best Match Show Resources per page
Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

American journal of clinical and experimental urology

Armstrong CM, Gao AC.
PMID: 26309896
Am J Clin Exp Urol. 2015 Aug 08;3(2):64-76. eCollection 2015.

Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). At present, the approved chemotherapies for CRPC include systemic drugs (docetaxel and cabazitaxel) and agents that target androgen signaling, including enzalutamide and abiraterone. While up...

Cite
Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015;3(2):64-76
Armstrong, C. M., & Gao, A. C. (2015). Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. American journal of clinical and experimental urology, 3(2), 64-76.
Armstrong, Cameron M, and Gao, Allen C. "Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies." American journal of clinical and experimental urology vol. 3,2 (2015): 64-76.
Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015 Aug 08;3(2):64-76. eCollection 2015. PMID: 26309896; PMCID: PMC4539108.
Copy Download .nbib Format: NLM
Neuroendocrine differentiation of prostate cancer: a review.

American journal of clinical and experimental urology

Parimi V, Goyal R, Poropatich K, Yang XJ.
PMID: 25606573
Am J Clin Exp Urol. 2014 Dec 09;2(4):273-85. eCollection 2014.

Neuroendocrine cells are one of the epithelial populations in the prostate. Neuroendocrine differentiation (NED) has been observed in prostate cancer. In addition to small cell neuroendocrine carcinomas and carcinoid tumors of the prostate, prostatic adenocarcinomas may have NED. The...

Cite
Parimi V, Goyal R, Poropatich K, et al. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014;2(4):273-85
Parimi, V., Goyal, R., Poropatich, K., & Yang, X. J. (2014). Neuroendocrine differentiation of prostate cancer: a review. American journal of clinical and experimental urology, 2(4), 273-85.
Parimi, Vamsi, et al. "Neuroendocrine differentiation of prostate cancer: a review." American journal of clinical and experimental urology vol. 2,4 (2014): 273-85.
Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014 Dec 09;2(4):273-85. eCollection 2014. PMID: 25606573; PMCID: PMC4297323.
Copy Download .nbib Format: NLM
The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years.

American journal of clinical and experimental urology

Kosaka T, Mizuno R, Shinojima T, Miyajima A, Kikuchi E, Tanaka N, Shinoda K, Morita S, Mikami S, Oya M.
PMID: 25606579
Am J Clin Exp Urol. 2014 Dec 25;2(4):332-6. eCollection 2014.

To investigate the appropriate cut-off level of PSA or other clinical parameters at aged ≤ 50 years. The rate of detection of PCa in young men will continue to rise associated with the advancement of the current and evolving...

Cite
Kosaka T, Mizuno R, Shinojima T, et al. The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years. Am J Clin Exp Urol. 2014;2(4):332-6
Kosaka, T., Mizuno, R., Shinojima, T., Miyajima, A., Kikuchi, E., Tanaka, N., Shinoda, K., Morita, S., Mikami, S., & Oya, M. (2014). The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years. American journal of clinical and experimental urology, 2(4), 332-6.
Kosaka, Takeo, et al. "The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years." American journal of clinical and experimental urology vol. 2,4 (2014): 332-6.
Kosaka T, Mizuno R, Shinojima T, Miyajima A, Kikuchi E, Tanaka N, Shinoda K, Morita S, Mikami S, Oya M. The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years. Am J Clin Exp Urol. 2014 Dec 25;2(4):332-6. eCollection 2014. PMID: 25606579; PMCID: PMC4297329.
Copy Download .nbib Format: NLM
De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review.

American journal of clinical and experimental urology

Acosta-Gonzalez G, Qin J, Wieczorek R, Melamed J, Deng FM, Zhou M, Makarov D, Ye F, Pei Z, Pincus MR, Lee P.
PMID: 25606580
Am J Clin Exp Urol. 2014 Dec 25;2(4):337-42. eCollection 2014.

Large cell neuroendocrine carcinoma of the prostate (LCNEC), de novo in particular, is an extremely rare entity that has only been described in the literature in case reports. Historically, the majority of the cases of LCNEC reported in the...

Cite
Acosta-Gonzalez G, Qin J, Wieczorek R, et al. De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review. Am J Clin Exp Urol. 2014;2(4):337-42
Acosta-Gonzalez, G., Qin, J., Wieczorek, R., Melamed, J., Deng, F. M., Zhou, M., Makarov, D., Ye, F., Pei, Z., Pincus, M. R., & Lee, P. (2014). De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review. American journal of clinical and experimental urology, 2(4), 337-42.
Acosta-Gonzalez, Gabriel, et al. "De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review." American journal of clinical and experimental urology vol. 2,4 (2014): 337-42.
Acosta-Gonzalez G, Qin J, Wieczorek R, Melamed J, Deng FM, Zhou M, Makarov D, Ye F, Pei Z, Pincus MR, Lee P. De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review. Am J Clin Exp Urol. 2014 Dec 25;2(4):337-42. eCollection 2014. PMID: 25606580; PMCID: PMC4297330.
Copy Download .nbib Format: NLM
Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D.

American journal of clinical and experimental urology

Jarrard D, Konety B, Huang W, Downs T, Kolesar J, Kim KM, Havighurst T, Slaton J, House MG, Parnes HL, Bailey HH.
PMID: 27766277
Am J Clin Exp Urol. 2016 Sep 20;4(2):17-27. eCollection 2016.

INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) represents an important target for chemoprevention given its prolonged natural history and high prevalence. Epidemiologic and laboratory data suggest that vitamin D and genistein (soy isoflavone) may decrease PCa progression. The effect of...

Cite
Jarrard D, Konety B, Huang W, et al. Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D. Am J Clin Exp Urol. 2016;4(2):17-27
Jarrard, D., Konety, B., Huang, W., Downs, T., Kolesar, J., Kim, K. M., Havighurst, T., Slaton, J., House, M. G., Parnes, H. L., & Bailey, H. H. (2016). Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D. American journal of clinical and experimental urology, 4(2), 17-27.
Jarrard, David, et al. "Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D." American journal of clinical and experimental urology vol. 4,2 (2016): 17-27.
Jarrard D, Konety B, Huang W, Downs T, Kolesar J, Kim KM, Havighurst T, Slaton J, House MG, Parnes HL, Bailey HH. Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D. Am J Clin Exp Urol. 2016 Sep 20;4(2):17-27. eCollection 2016. PMID: 27766277; PMCID: PMC5069272.
Copy Download .nbib Format: NLM
TBL1XR1 in physiological and pathological states.

American journal of clinical and experimental urology

Li JY, Daniels G, Wang J, Zhang X.
PMID: 26069883
Am J Clin Exp Urol. 2015 Apr 25;3(1):13-23. eCollection 2015.

Transducin (beta)-like 1X related protein 1 (TBL1XR1/TBLR1) is an integral subunit of the NCoR (nuclear receptor corepressor) and SMRT (silencing mediator of retinoic acid and thyroid hormone receptors) repressor complexes. It is an evolutionally conserved protein that shares high...

Cite
Li JY, Daniels G, Wang J, et al. TBL1XR1 in physiological and pathological states. Am J Clin Exp Urol. 2015;3(1):13-23
Li, J. Y., Daniels, G., Wang, J., & Zhang, X. (2015). TBL1XR1 in physiological and pathological states. American journal of clinical and experimental urology, 3(1), 13-23.
Li, Jian Yi, et al. "TBL1XR1 in physiological and pathological states." American journal of clinical and experimental urology vol. 3,1 (2015): 13-23.
Li JY, Daniels G, Wang J, Zhang X. TBL1XR1 in physiological and pathological states. Am J Clin Exp Urol. 2015 Apr 25;3(1):13-23. eCollection 2015. PMID: 26069883; PMCID: PMC4446378.
Copy Download .nbib Format: NLM
Clear cell sarcoma of the penis: a case report.

American journal of clinical and experimental urology

Ito T, Melamed J, Perle MA, Alukal J.
PMID: 26069887
Am J Clin Exp Urol. 2015 Apr 25;3(1):43-7. eCollection 2015.

Clear cell sarcoma of the penis is exceedingly rare with only one prior case involving the penis reported in the literature. We present the case of a 32 year old male who presented with an infiltrative neoplasm at the...

Cite
Ito T, Melamed J, Perle MA, et al. Clear cell sarcoma of the penis: a case report. Am J Clin Exp Urol. 2015;3(1):43-7
Ito, T., Melamed, J., Perle, M. A., & Alukal, J. (2015). Clear cell sarcoma of the penis: a case report. American journal of clinical and experimental urology, 3(1), 43-7.
Ito, Timothy, et al. "Clear cell sarcoma of the penis: a case report." American journal of clinical and experimental urology vol. 3,1 (2015): 43-7.
Ito T, Melamed J, Perle MA, Alukal J. Clear cell sarcoma of the penis: a case report. Am J Clin Exp Urol. 2015 Apr 25;3(1):43-7. eCollection 2015. PMID: 26069887; PMCID: PMC4446382.
Copy Download .nbib Format: NLM
Infections and inflammation in prostate cancer.

American journal of clinical and experimental urology

Sfanos KS, Isaacs WB, De Marzo AM.
PMID: 25110720
Am J Clin Exp Urol. 2013 Dec 25;1(1):3-11.

The frequent observation of both acute and chronic inflammation of unknown stimulus in the adult prostate has motivated a large body of research aimed at identifying potential infectious agents that may elicit prostatic inflammation. The overarching hypothesis is that...

Cite
Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. Am J Clin Exp Urol. 2013;1(1):3-11
Sfanos, K. S., Isaacs, W. B., & De Marzo, A. M. (2013). Infections and inflammation in prostate cancer. American journal of clinical and experimental urology, 1(1), 3-11.
Sfanos, Karen S, et al. "Infections and inflammation in prostate cancer." American journal of clinical and experimental urology vol. 1,1 (2013): 3-11.
Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. Am J Clin Exp Urol. 2013 Dec 25;1(1):3-11. PMID: 25110720; PMCID: PMC4219279.
Copy Download .nbib Format: NLM
Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion.

American journal of clinical and experimental urology

Lo UG, Bao J, Cen J, Yeh HC, Luo J, Tan W, Hsieh JT.
PMID: 30906803
Am J Clin Exp Urol. 2019 Feb 18;7(1):31-45. eCollection 2019.

Interferon is known as a pleiotropic factor in innate immunity, cancer immunity and therapy. Despite an objective short-term response of interferon (IFN) therapy in renal cell carcinoma (RCC) patients, the potential adverse effect of IFN on RCC cells is...

Cite
Lo UG, Bao J, Cen J, et al. Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion. Am J Clin Exp Urol. 2019;7(1):31-45
Lo, U. G., Bao, J., Cen, J., Yeh, H. C., Luo, J., Tan, W., & Hsieh, J. T. (2019). Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion. American journal of clinical and experimental urology, 7(1), 31-45.
Lo, U-Ging, et al. "Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion." American journal of clinical and experimental urology vol. 7,1 (2019): 31-45.
Lo UG, Bao J, Cen J, Yeh HC, Luo J, Tan W, Hsieh JT. Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion. Am J Clin Exp Urol. 2019 Feb 18;7(1):31-45. eCollection 2019. PMID: 30906803; PMCID: PMC6420704.
Copy Download .nbib Format: NLM
Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model.

American journal of clinical and experimental urology

Jia W, Schults AJ, Jensen MM, Ye X, Alt JA, Prestwich GD, Oottamasathien S.
PMID: 29034266
Am J Clin Exp Urol. 2017 Sep 01;5(2):10-17. eCollection 2017.

Our goal was to evaluate the pain response in an LL-37 induced murine model for interstitial cystitis/painful bladder syndrome (IC/PBS). In particular, we sought to characterize the dose dependence, time-course, and relationship of LL-37 induced bladder inflammation and pain....

Cite
Jia W, Schults AJ, Jensen MM, et al. Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model. Am J Clin Exp Urol. 2017;5(2):10-17
Jia, W., Schults, A. J., Jensen, M. M., Ye, X., Alt, J. A., Prestwich, G. D., & Oottamasathien, S. (2017). Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model. American journal of clinical and experimental urology, 5(2), 10-17.
Jia, Wanjian, et al. "Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model." American journal of clinical and experimental urology vol. 5,2 (2017): 10-17.
Jia W, Schults AJ, Jensen MM, Ye X, Alt JA, Prestwich GD, Oottamasathien S. Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model. Am J Clin Exp Urol. 2017 Sep 01;5(2):10-17. eCollection 2017. PMID: 29034266; PMCID: PMC5636891.
Copy Download .nbib Format: NLM
Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer.

American journal of clinical and experimental urology

Duan Z, Miller HD, Fu X, Ge D, Jin B, Moustafa AA, Lan R, Zhang K, Chen Z, You Z.
PMID: 31511831
Am J Clin Exp Urol. 2019 Aug 25;7(4):249-261. eCollection 2019.

Interleukin-17 (IL-17) has been demonstrated to promote development of a variety of cancers including prostate cancer in genetically modified mouse models. IL-17 is the main product secreted by T helper 17 (Th17) cells. A recent study has shown that...

Cite
Duan Z, Miller HD, Fu X, et al. Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer. Am J Clin Exp Urol. 2019;7(4):249-261
Duan, Z., Miller, H. D., Fu, X., Ge, D., Jin, B., Moustafa, A. A., Lan, R., Zhang, K., Chen, Z., & You, Z. (2019). Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer. American journal of clinical and experimental urology, 7(4), 249-261.
Duan, Zhenling, et al. "Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer." American journal of clinical and experimental urology vol. 7,4 (2019): 249-261.
Duan Z, Miller HD, Fu X, Ge D, Jin B, Moustafa AA, Lan R, Zhang K, Chen Z, You Z. Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer. Am J Clin Exp Urol. 2019 Aug 25;7(4):249-261. eCollection 2019. PMID: 31511831; PMCID: PMC6734037.
Copy Download .nbib Format: NLM
The dysfunctional lipids in prostate cancer.

American journal of clinical and experimental urology

Dang Q, Chen YA, Hsieh JT.
PMID: 31511833
Am J Clin Exp Urol. 2019 Aug 15;7(4):273-280. eCollection 2019.

Prostate cancer (PCa) is well-recognized as a lipid-enriched tumor. Lipids represent a diverse array of molecules essential to the cellular structure, defense, energy, and communication. Lipid metabolism can often become dysregulated during tumor development. The increasing body of knowledge...

Cite
Dang Q, Chen YA, Hsieh JT. The dysfunctional lipids in prostate cancer. Am J Clin Exp Urol. 2019;7(4):273-280
Dang, Q., Chen, Y. A., & Hsieh, J. T. (2019). The dysfunctional lipids in prostate cancer. American journal of clinical and experimental urology, 7(4), 273-280.
Dang, Qiang, et al. "The dysfunctional lipids in prostate cancer." American journal of clinical and experimental urology vol. 7,4 (2019): 273-280.
Dang Q, Chen YA, Hsieh JT. The dysfunctional lipids in prostate cancer. Am J Clin Exp Urol. 2019 Aug 15;7(4):273-280. eCollection 2019. PMID: 31511833; PMCID: PMC6734041.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 220 entries